Overview

The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2027-10-15

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of TAS-102 combined with bevacizumab as first-line therapy in patients with advanced colorectal cancer who could not tolerate or did not receive combined chemotherapy

Phase:

Phase 2

Details

Lead Sponsor:

The Second Affiliated Hospital of Shandong First Medical University

Treatments:

Bevacizumab